Key facts
- Notable investors include Newcastle University, Vespa Capital (London).
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Fibrofind
- ·The full record, as it builds
Funding rounds
No funding rounds for Fibrofind are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Fibrofind
Operator of a contract research company intended for pre-clinical drug development. The company offers research services for discovering medicines for liver, kidney, and lung diseases and has established human tissue models of fibrosis and inflammation in multiple organ systems that maintain the architectural integrity, functionality, and metabolic activities of the tissue over an extended period, enabling companies to get drug testing services for different diseases.
- Sector
- Business Products and Services (B2B)
- HQ
- Gateshead, United Kingdom
- Founded
- 2018
- Employees
- 22
- Website
- fibrofind.com/
- Ownership
- Privately Held (backing)
Fibrofind doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Fibrofind shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Fibrofind in its N-PORT filings yet. We sweep new filings monthly.